10 June 2009
Ellex Reaches Milestone in SLT Laser Sales
Adelaide, Australia, 10 June 2009 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced that it now has in place more than 1,000 SLT (Selective Laser Trabeculoplasty) laser systems on a global basis.
Ellex was one of the first companies to manufacture SLT lasers, introducing its own SLT systems – the Ellex Tango™ and Solo™ – into markets outside of the US in 2005. It now has more than 1,000 of these systems in use, supported by a rapidly expanding sales and support network.
In addition, Ellex partnered with Coherent (now Lumenis) in 2001 to develop and supply the Selecta Duet SLT laser system. This partnership resulted in more than 500 systems through March 2006, when the agreement came to an end.
“This is a tremendous milestone for Ellex and one that speaks to the utility of SLT in the treatment of glaucoma,” said Simon Luscombe, Ellex CEO. “This milestone also underpins our continued dedication to advance the role of ophthalmic laser technology for ophthalmologists around the world.”
SLT from Ellex
Ellex offers two laser systems for SLT – the Tango™ SLT/YAG combination laser and the Solo™ SLT laser. Each system’s fully integrated design ensures more stable, reliable and consistent energy, while minimizing system down time. This is because there are no exposed fiber optic or electrical cables to accidentally damage.
Both the Ellex Tango™ and Solo™ provide greater precision, superior energy control and the fastest repetition rate in the industry at 3 hertz. This enables ophthalmologists to perform quick and highly accurate SLT treatment customized to the individual patient’s response.
Value-Added SLT Program
In order to maximize the potential of SLT for ophthalmologists, Ellex has developed a Value-Added SLT Program.
First introduced in 2006, this program delivers a number of tools designed to increase the visibility of SLT among patients, and provides a wealth of treatment information based on the extensive experience of doctors, researchers and clinicians worldwide. These tools include the website: www.slt-ellex.com – a resource of clinical and technical information that is designed to help SLT practitioners incorporate the treatment into their practice. Some of the points covered on the website include:
- How to qualify patients for treatment
- Optimal treatment techniques
- The latest SLT research studies
- Also provides a forum for networking with peers and industry experts.
With volume 10 soon to be available, another tool is the Regenerate SLT newsletter. Designed specifically for physicians, Regenerate explores numerous clinical and practical issues concerning SLT, including treatment tips, literature reviews and the latest clinical study updates. Plus, every issue features the insights and expertise of guest authors who are among the world’s most experienced SLT practitioners.
As part of the Value-Added SLT program, Ellex has partnered with physicians to help raise awareness of SLT to patients.
“Many glaucoma patients remain unaware that there is a treatment that is safe and efficacious, without the possible side effects and constraints associated with medications and surgical procedures,” said Sheng Lim M.D., Consultant Ophthalmic Surgeon and Glaucoma specialist at St Thomas’ Hospital, London. “Ellex has taken an active role in helping to increase patient awareness about SLT.”
Some of the materials available to ophthalmologists include practice-marketing tools, including a media press kit than can be used to raise the visibility of SLT, and a patient education brochure. The brochure is accompanied by a poster for use in the physician’s waiting room – written in non-clinical, easy-to-understand language.
Gentle and non-invasive, SLT has increasingly become the therapy of choice for glaucoma management. This advanced, non-thermal treatment works by stimulating a natural healing response in the body to manage intraocular pressure, promoting cellular regeneration without the burn and scar tissue associated with other laser treatments. Highly effective, SLT is used as a primary treatment option for early stages of open angle glaucoma, and can be used in combination with drug therapy or as an alternative therapy when drugs fail. It is also a flexible treatment option, given that it can be repeated, if necessary, depending on the individual patient’s response.
For additional information about SLT, please visit www.slt-ellex.com.
Ellex Medical Lasers Limited (ASX:ELX) designs, manufactures and sells a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye diseases. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound devices for ophthalmology, initiating the expansion of its product line beyond lasers. Ellex maintains a strong emphasis on intellectual property and research into new and better treatments to manage and treat the leading causes of blindness.